Biohaven is betting big on targeting brain disorders such as Parkinson’s and potentially Alzheimer’s.
The Connecticut biotech recently announced that it in-licensed an oral, brain-penetrant dual inhibitor of TYK2 and JAK1 from Chinese biotech HighlightLL Pharmaceutical. The deal includes $20 million upfront in a 50/50 split between cash and Biohaven equity. The offer includes an additional $950 million in development and commercial milestones, plus royalties.